Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eran Ophir

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Blood|November 4, 2010
CTLs respond with activation and granule secretion when serving as targets for T-cell recognitionOren Milstein, David Hagin, Assaf Lask, et al.
Blood|March 1, 2013
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsAssaf Lask, Eran Ophir, Noga Or-Geva, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 2011
TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagementAssaf Lask, Polina Goichberg, Adva Cohen, et al.
Plos One|February 13, 2014
Procedures for behavioral experiments in head-fixed miceZengcai V Guo, S Andrew Hires, Nuo Li, et al.
Blood|December 11, 2012
Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cellsEran Ophir, Noga Or-Geva, Irina Gurevich, et al.
Cancer Immunology Research|January 20, 2019
Mouse PVRIG Has CD8<sup>+</sup> T Cell-Specific Coinhibitory Functions and Dampens Antitumor ImmunityBenjamin Murter, Xiaoyu Pan, Eran Ophir, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2021
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockadeKyle Hansen, Sandeep Kumar, Kathryn Logronio, et al.
Cancer Immunology Research|January 20, 2019
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8<sup>+</sup> T-cell FunctionSarah Whelan, Eran Ophir, Maya F Kotturi, et al.
Cancer Immunology Research|May 16, 2024
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell-Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed TumorsZoya Alteber, Gady Cojocaru, Roy Z Granit, et al.
Cancer Immunology Research|April 9, 2024
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor EffectsAssaf Menachem, Zoya Alteber, Gady Cojocaru, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood|November 4, 2010
CTLs respond with activation and granule secretion when serving as targets for T-cell recognitionOren Milstein, David Hagin, Assaf Lask, et al.
Blood|March 1, 2013
A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsAssaf Lask, Eran Ophir, Noga Or-Geva, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 2011
TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagementAssaf Lask, Polina Goichberg, Adva Cohen, et al.
Plos One|February 13, 2014
Procedures for behavioral experiments in head-fixed miceZengcai V Guo, S Andrew Hires, Nuo Li, et al.
Blood|December 11, 2012
Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cellsEran Ophir, Noga Or-Geva, Irina Gurevich, et al.
Cancer Immunology Research|January 20, 2019
Mouse PVRIG Has CD8<sup>+</sup> T Cell-Specific Coinhibitory Functions and Dampens Antitumor ImmunityBenjamin Murter, Xiaoyu Pan, Eran Ophir, et al.
Cancer Immunology, Immunotherapy : CII|April 27, 2021
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockadeKyle Hansen, Sandeep Kumar, Kathryn Logronio, et al.
Cancer Immunology Research|January 20, 2019
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8<sup>+</sup> T-cell FunctionSarah Whelan, Eran Ophir, Maya F Kotturi, et al.
Cancer Immunology Research|May 16, 2024
PVRIG is Expressed on Stem-Like T Cells in Dendritic Cell-Rich Niches in Tumors and Its Blockade May Induce Immune Infiltration in Non-Inflamed TumorsZoya Alteber, Gady Cojocaru, Roy Z Granit, et al.
Cancer Immunology Research|April 9, 2024
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor EffectsAssaf Menachem, Zoya Alteber, Gady Cojocaru, et al.
Pageof 3